title: The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.
abstract: Parkinson's disease (PD) is a neurodegenerative movement disorder due to selective loss of dopaminergic neurons of mesencephalic substantia nigra pars compacta (SNC) with debilitating motor symptoms. Current treatments for PD afford symptomatic relief with no prevention of disease progression. Due to the antioxidant and neuroprotective potential of sinapic acid, this study was conducted to evaluate whether this agent could be of benefit in an experimental model of early PD in rat. Unilateral intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were pretreated p.o. with sinapic acid at doses of 10 or 20 mg/kg. One week after surgery, apomorphine caused significant contralateral rotations, a significant reduction in the number of Nissl-stained and tyrosine hydroxylase (TH)-positive neurons and a significant increase of iron reactivity on the left side of SNC. Meanwhile, malondialdehyde (MDA) and nitrite levels in midbrain homogenate significantly increased and activity of superoxide dismutase (SOD) significantly reduced in the 6-OHDA-lesioned group. In addition, sinapic acid at a dose of 20 mg/kg significantly improved turning behavior, prevented loss of SNC dopaminergic neurons, lowered iron reactivity, and attenuated level of MDA and nitrite. These results indicate the neuroprotective potential of sinapic acid against 6-OHDA neurotoxicity that is partially due to the attenuation of oxidative stress and possibly lowering nigral iron level.
authors.affiliation: Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
authors.forename: Kobra
authors.initials: K
authors.lastname: Zare
authors.forename: Akram
authors.initials: A
authors.lastname: Eidi
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Roghani
authors.forename: Ali Haeri
authors.initials: AH
authors.lastname: Rohani
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D001058:Apomorphine / Q000633:toxicity; D002452:Cell Count; D003373:Coumaric Acids / Q000627:therapeutic use*; D059290:Dopaminergic Neurons / Q000473:pathology; D007501:Iron / Q000032:analysis; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008636:Mesencephalon / Q000737:chemistry; D009419:Nerve Tissue Proteins / Q000032:analysis; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D009573:Nitrites / Q000032:analysis; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D008517:Phytotherapy; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D013239:Stereotyped Behavior / Q000187:drug effects; D013482:Superoxide Dismutase / Q000032:analysis; D017392:Thiobarbituric Acid Reactive Substances / Q000032:analysis; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
chemical_list: D000975:Antioxidants; D003373:Coumaric Acids; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D009573:Nitrites; D017392:Thiobarbituric Acid Reactive Substances; C073734:sinapinic acid; D016627:Oxidopamine; D007501:Iron; D014446:Tyrosine 3-Monooxygenase; D013482:Superoxide Dismutase; D001058:Apomorphine